United Therapeutics company profile

UTHR · NASDAQ · USD

Compare United Therapeutics
$584.10Change from previous close: −0.64%Absolute change: −$3.78

Close · November 17, 2026

Company profile

United Therapeutics has 1,400 employees and is headquartered in Silver Spring, United States.

Based in Silver Spring, Maryland, United Therapeutics Corporation has existed since 1996 and develops and commercializes products for patients with chronic and life-threatening diseases. Its treatments for pulmonary arterial hypertension form the core of its range, including the inhaled Tyvaso DPI and Nebulized Tyvaso, the injectable Remodulin, the tablet Orenitram and the oral Adcirca. It also sells Unituxin, a monoclonal antibody for high-risk neuroblastoma, and the Remunity Pump, a pump and controller for Remodulin. Its pipeline spans idiopathic pulmonary fibrosis, organ xenotransplantation and regenerative medicine, developed in part through licensing and collaboration agreements with DEKA Research & Development Corp., MannKind Corporation and Arena Pharmaceuticals, Inc.

In the fiscal year ended December 2025, revenue rose 10.6% to 3.2 billion US dollars, and net profit reached 1.3 billion dollars. The United States generated 95.4% of revenue, while non-US markets accounted for 4.6%. The company employed 1,400 people.

Company facts

Industry
Drug Manufacturers - Specialty & Generic
Headquarters
1000 Spring Street, 20910, Silver Spring
Employees
1,400
Chief executive
Martine Rothblatt
Founded
1996
Fiscal year
January - December
Listing
UTHR · NASDAQ
Currency
USD
ISIN
US91307C1027

United Therapeutics and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
United TherapeuticsUTHRUnited States$25.04B1,40039.4%22.2
ViatrisVTRSUnited States$23.58B30,000——
ZoetisZTSUnited States$33.92B14,50037.9%14.1
Neurocrine BiosciencesNBIXUnited States$16.73B2,50026.6%24.5
Teva Pharmaceutical IndustriesTEVAUnited States$49.67B31,17319.8%99.0
Hims & Hers HealthHIMSUnited States$4.13B2,442-6.4%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare United Therapeutics with its competitors